) The Core facility is responsible for providing technical, clinical, and analytical support to Projects 1, 2 and 3 and for providing administrative focus to the entire Project. It will perform four functions. The first will be the support of Project 1 in the realm of the monitoring of patients enrolled in the double-blind randomized control studies. This will include the frequent contacting of patients and of their primary skin care physicians (PSCPs) to ensure that records of all skin treatments are available and to ensure that patients are following the Study protocols, and have a central contact person to whom they can address questions about the study should the Clinical Investigators monitoring the patients not be available. The second will be in the realm of data management - the ensuring that data from the Clinical Investigators, the PSCPs, laboratory testing (including the testing of blood for tea component levels), etc. is gathered and is entered into a data base for analysis. Data also will be stored on all agents tested - e.g. in the acute phototoxicity prevention studies in Project 3 and the murine chronic chemoprevention studies in Project 2. The third will be the analysis of the data utilizing appropriate biostatistical testing. The fourth will be the storage of patient specimens both DNA as a resource for future genotyping and also plasma as a resource for future determination e.g. of micronutrients. This centralization of these future will ensure a level of quality control and """"""""institutional memory"""""""" otherwise unattainable in a complex multi- center Project such as this.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program--Cooperative Agreements (U19)
Project #
5U19CA081888-04
Application #
6616329
Study Section
Project Start
2002-07-19
Project End
2003-06-30
Budget Start
Budget End
Support Year
4
Fiscal Year
2002
Total Cost
Indirect Cost
Name
University of California San Francisco
Department
Type
DUNS #
073133571
City
San Francisco
State
CA
Country
United States
Zip Code
94143
Tang, Jean Y; Xiao, Tony Zheng; Oda, Yuko et al. (2011) Vitamin D3 inhibits hedgehog signaling and proliferation in murine Basal cell carcinomas. Cancer Prev Res (Phila) 4:744-51
Davari, Parastoo; Hebert, Jennifer L; Albertson, Donna G et al. (2010) Loss of Blm enhances basal cell carcinoma and rhabdomyosarcoma tumorigenesis in Ptch1+/- mice. Carcinogenesis 31:968-73
Tang, Jean Y; Wu, Angela; Linos, Eleni et al. (2010) High prevalence of vitamin D deficiency in patients with basal cell nevus syndrome. Arch Dermatol 146:1105-10
Tang, Jean Y; Aszterbaum, Michelle; Athar, Mohammad et al. (2010) Basal cell carcinoma chemoprevention with nonsteroidal anti-inflammatory drugs in genetically predisposed PTCH1+/- humans and mice. Cancer Prev Res (Phila) 3:25-34
So, Po-Lin; Fujimoto, Michele A; Epstein Jr, Ervin H (2008) Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol Cancer Ther 7:1275-84
Athar, Mohammad; Tang, Xiuwei; Lee, Juliette L et al. (2006) Hedgehog signalling in skin development and cancer. Exp Dermatol 15:667-77
Bickers, David R; Athar, Mohammad (2006) Oxidative stress in the pathogenesis of skin disease. J Invest Dermatol 126:2565-75
So, Po-Lin; Langston, Alexander W; Daniallinia, Nancy et al. (2006) Long-term establishment, characterization and manipulation of cell lines from mouse basal cell carcinoma tumors. Exp Dermatol 15:742-50
Lee, Juliette Lois; Kim, Arianna; Kopelovich, Levy et al. (2005) Differential expression of E prostanoid receptors in murine and human non-melanoma skin cancer. J Invest Dermatol 125:818-25
Vogt, Annika; Hebert, Jennifer; Hwang, Jimmy et al. (2005) Anti-rejection drug treatment increases basal cell carcinoma burden in Ptch1+/- mice. J Invest Dermatol 124:263-7

Showing the most recent 10 out of 26 publications